MOUNTAIN VIEW, Calif., May 6, 2011 /PRNewswire/ — Hotspur
Technologies, Inc. announced today that it has received CE Mark
approval for the IQCath Balloon Dilatation Catheter, allowing the
company to introduce the novel technology to markets outside of the
United States. The IQCath catheter utilizes Hotspur’s
groundbreaking technology to combine multiple functions into a
single device that can potentially make procedures to open blocked
blood vessels more efficient and cost-effective than current
Over 2 million patients worldwide require dialysis due to
end-stage renal disease (ESRD) with annual expenditures for
dialysis products and services forecasted to be over $65 billion,
making it one of the most costly segments of medical care.
The need for continued dialysis to filter the blood of these
ESRD patients results in repeated blockages within their vascular
access sites. On average, these patients require multiple
interventions each year in order to keep these sites free from
blockages and subsequent clot formation.
These blockages are most often treated with standard balloon
angioplasty, a minimally invasive procedure that uses a catheter
and balloon to widen narrowed vessels. Unlike existing
angioplasty balloons, the IQCath catheter enables physicians to
conduct multiple functions that may be required to clear the
blockage with a single catheter.
When treating blocked vascular access sites, physicians
typically must use multiple catheters to restore blood flow by
removing clot and opening the blockage. During a single
procedure, these devices are removed and reinserted several times,
which often proves to be time consuming and expensive.
The IQCath catheter is indicated for use within synthetic
dialysis access grafts to remove embolic material and to dilate
obstructive blockages. Based on the use of Hotspur’s
proprietary VisioValve™ technology, the IQCath catheter